OMDA — what changed in the latest 10-Q
A section-by-section comparison of OMDA's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-07 vs the prior 10-Q · 2026-05-08
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +56 | −27 | ~8 | 43 |
| Market risk (Item 3) | Text added/removed | 0 | 0 | ~1 | 2 |
| Controls & procedures | Text added/removed | 0 | −1 | ~3 | 9 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | Some risk factors updated | +27 | −27 | ~44 | 331 |
| Other information | Text added/removed | 0 | −4 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-07
Under the OBBBA and newly enacted Section 174A of the Code, taxpayers may accelerate the recovery of previously capitalized domestic research and development expenditures that remained unamortized as of 2025, either entirely in 2025 or ratably over 2025 and 2026. We intend to elect to recover these …
Net income (loss) and comprehensive income (loss)6 %(9)%2 %(13)%
Comparison of the Three and Six Months Ended June 30, 2026 and 2025
Total revenue increased by $26.5 million, or 43%, for the three months ended June 30, 2026 compared to the three months ended June 30, 2025. Total revenue increased by $49.5 million, or 43% for the six months ended June 30, 2026 compared to the six months ended June 30, 2025.
Three Months Ended June 30, 2026 Compared with the Same Period in 2025
Text removed vs the prior filing · source: 10-Q · 2026-05-08
Under the OBBBA and newly enacted Section 174A of the Code, taxpayers may accelerate the recovery of previously capitalized domestic research and development expenditures that remained unamortized as of 2025, either
entirely in 2025 or ratably over 2025 and 2026. We have elected to recover these costs ratably over 2025 and 2026 and recognized a deduction of approximately $36.1 million in 2025 to such expenditures.
Comparison of the Three Months Ended March 31, 2026 and 2025
Total revenue increased by $23.1 million, or 42%, for the three months ended March 31, 2026 compared to the three months ended March 31, 2025.
Services revenue increased by $20.1 million, or 41%, for the three months ended March 31, 2026 compared to the three months ended March 31, 2025, primarily driven by an increase of $24.1 million related to growth in total members due to acquisition of new customers and channel partners, sales of add…
Controls & procedures
Text removed vs the prior filing · source: 10-Q · 2026-05-08
•Continuing to hire qualified technical accounting and financial reporting personnel with public company experience to perform control activities;
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-08-07
member engagement, clinical outcomes, and cost savings for our customers and channel partners, our business, financial condition, results of operations, and prospects could be materially and adversely affected.
PBM that accounted for 32% of our revenue. For the year ended December 31, 2025, we had one health plan or PBM that accounted for 32% of our revenue, and a second health plan or PBM that accounted for 33% of our revenue. Each of these health plans or PBMs are affiliates of The Cigna Group. In genera…
We rely largely on information supplied by our customers and channel partners to conduct outreach campaigns directed at covered individuals, and though we often assist with these outreach campaigns, we do not control our
customers’ or channel partners’ enrollment outreach schedules. As a result, if they are unwilling or unable to supply information needed for outreach campaigns or are unwilling or unable to enable outreach campaigns generally, or if enrollment launch dates are delayed, we could fail to meet our enro…
For our business strategy to be successful, our suppliers and partners must be able to provide us with devices, supplies, connectivity, and services in sufficient quantities, in compliance with regulatory requirements and quality control standards, in accordance with agreed-upon specifications, at a…
Text removed vs the prior filing · source: 10-Q · 2026-05-08
•We will need to increase the size of our organization, including our Care Teams, and we may experience difficulties in managing growth and attracting talent. A deterioration in our relationships with our employees and other service providers could have an adverse impact on our business.
operations, any of which could materially and adversely affect our business, financial condition, results of operations, and prospects.
of our key customers or channel partners could negatively impact our revenue as we work to obtain new customers or establish replacement channel partner relationships. Contracts with our key customers and channel partners may be terminated before their term expires for various reasons, subject to ce…
We rely largely on information supplied by our customers and channel partners to conduct outreach campaigns directed at covered individuals, and though we often assist with these outreach campaigns, we do not control our customers’ or channel partners’ enrollment outreach schedules. As a result, if …
For our business strategy to be successful, our suppliers and partners must be able to provide us with devices, supplies, connectivity, and services in sufficient quantities, in compliance with regulatory requirements and quality control standards, in accordance with agreed-upon specifications, at a…
Other information
Text removed vs the prior filing · source: 10-Q · 2026-05-08
•On March 13, 2026, Sean Duffy, our Chief Executive Officer and a member of our board of directors, individually and through a trust under which he is a beneficiary, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a “Rule 10b5-1 Pla…
•On March 14, 2026, Steve Cook, our Chief Financial Officer, adopted a Rule 10b5-1 Plan for the sale of up to (i) 394,831 shares of our common stock and (ii) the number of shares of our common stock Mr. Cook will receive following the vesting of restricted stock units covering an aggregate of 66,514…
•On March 13, 2026, Wei-Li Shao, our President, adopted a Rule 10b5-1 Plan for the sale of the number of shares of our common stock Mr. Shao will receive following the vesting of restricted stock units covering an aggregate of 85,913 shares of our common stock and the satisfaction of tax obligations…
•On March 13, 2026, Craig Gracey, our Chief Accounting Officer, adopted a Rule 10b5-1 Plan for the sale of up to 20,833 shares of our common stock and (ii) the number of shares of our common stock Mr. Gracey will receive following the vesting of restricted stock units covering an aggregate of 4,117 …
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice